

# Serena Guiducci

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8484653/publications.pdf>

Version: 2024-02-01

180  
papers

11,462  
citations

50170

46  
h-index

30848

102  
g-index

182  
all docs

182  
docs citations

182  
times ranked

10430  
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.5	1,705
3	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
4	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. <i>Arthritis Research</i> , 2002, 4, R11.	2.0	230
5	Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 924-934.	0.5	184
6	Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. <i>Rheumatology</i> , 2010, 49, 1374-1382.	0.9	172
7	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014, 48-49, 60-65.	3.0	170
8	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.5	168
9	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.5	160
10	Vascular complications of scleroderma. <i>Autoimmunity Reviews</i> , 2007, 6, 520-523.	2.5	157
11	Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2665-2678.	6.7	154
12	Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. <i>Arthritis Research and Therapy</i> , 2007, 9, 301.	1.6	150
13	Overexpression of VEGF <sub>165</sub> b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Leads to Insufficient Angiogenesis in Patients With Systemic Sclerosis. <i>Circulation Research</i> , 2011, 109, e14-26.	2.0	148
14	Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 390-395.	0.5	146
15	Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 482-496.	1.6	134
16	“To Be or Not To Be,” Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, 589-598.	1.6	126
17	Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. <i>Arthritis and Rheumatism</i> , 2004, 50, 3275-3285.	6.7	118
18	Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 1241-1254.	1.6	118

#	ARTICLE	IF	CITATIONS
19	COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. <i>Clinical Rheumatology</i> , 2020, 39, 3195-3204.	1.0	105
20	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	1.1	101
21	Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis. <i>Annals of Internal Medicine</i> , 2010, 153, 650.	2.0	100
22	The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 598-605.	0.5	97
23	Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1064-1072.	0.5	95
24	A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 253-262.	1.6	93
25	The relationship between plasma microparticles and disease manifestations in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2845-2853.	6.7	91
26	Interstitial lung disease in systemic sclerosis: where do we stand?. <i>European Respiratory Review</i> , 2015, 24, 411-419.	3.0	90
27	High frequency ultrasound measurement of digital dermal thickness in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1140-1143.	0.5	82
28	Systemic sclerosis and infections. <i>Autoimmunity Reviews</i> , 2008, 8, 36-40.	2.5	77
29	Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2011-2021.	0.5	75
30	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	2.9	75
31	Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1700-1709.	0.5	72
32	Flow-Mediated Vasodilation and Carotid Intima-Media Thickness in Systemic Sclerosis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 283-290.	1.8	70
33	Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 74-80.	0.5	70
34	Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. <i>Frontiers in Immunology</i> , 2018, 9, 2045.	2.2	67
35	Activin, a Grape Seed-derived Proanthocyanidin Extract, Reduces Plasma Levels of Oxidative Stress and Adhesion Molecules (ICAM-1, VCAM-1 and E-selectin) in Systemic Sclerosis. <i>Free Radical Research</i> , 2002, 36, 819-825.	1.5	66
36	Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. <i>Arthritis and Rheumatism</i> , 2006, 54, 3022-3033.	6.7	64

#	ARTICLE	IF	CITATIONS
37	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the <i>TNFAIP3</i> locus as a risk factor for polyautoimmunity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2746-2752.	6.7	63
38	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 183-192.	1.6	63
39	The Role of Infections in the Immunopathogenesis of Systemic Sclerosis—Evidence from Serological Studies. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 627-632.	1.8	61
40	Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2015, 14, 314-322.	2.5	60
41	Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 124-128.	0.5	60
42	Functional disability and its predictors in systemic sclerosis: a study from the DeSScipher project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	0.9	60
43	Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 72-76.	0.9	57
44	A model of anti-angiogenesis: differential transcriptome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. <i>Arthritis Research and Therapy</i> , 2006, 8, R115.	1.6	56
45	The antiangiogenic tissue kallikrein pattern of endothelial cells in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3618-3628.	6.7	55
46	Impaired Angiogenesis in Systemic Sclerosis: The Emerging Role of the Antiangiogenic VEGF165b Splice Variant. <i>Trends in Cardiovascular Medicine</i> , 2011, 21, 204-210.	2.3	53
47	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. <i>Rheumatology</i> , 2022, 61, 1600-1609.	0.9	53
48	Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis. <i>Chest</i> , 2020, 158, 1515-1525.	0.4	50
49	Musculoskeletal involvement in systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 339-350.	1.4	46
50	Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1876-1878.	0.5	46
51	Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in Italy. <i>Journal of Rheumatology</i> , 2009, 36, 1464-1469.	1.0	45
52	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	1.6	45
53	Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). <i>Rheumatology</i> , 2020, 59, 1938-1948.	0.9	42
54	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	2.2	42

#	ARTICLE	IF	CITATIONS
55	A genetic variation located in the promoter region of the <i>UPAR</i> ( <i>CD87</i> ) gene is associated with the vascular complications of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 247-256.	6.7	41
56	Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. <i>Scientific Reports</i> , 2017, 7, 13293.	1.6	41
57	Association of a Functional Polymorphism in the Matrix Metalloproteinase-12 Promoter Region with Systemic Sclerosis in an Italian Population. <i>Journal of Rheumatology</i> , 2010, 37, 1852-1857.	1.0	39
58	Increased plasma levels of the VEGF <sub>165</sub> splice variant are associated with the severity of nailfold capillary loss in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1425-1427.	0.5	39
59	Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1541-1549.	0.5	38
60	<i>Very early</i> versus <i>early</i> disease: the evolving definition of the "many faces" of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 319-321.	0.5	37
61	Differential expression of junctional adhesion molecules in different stages of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 247-257.	6.7	36
62	Implantable Cardioverter Defibrillator Prevents Sudden Cardiac Death in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 1617-1621.	1.0	35
63	Calcinosis in systemic sclerosis: subsets, distribution and complications. <i>Rheumatology</i> , 2016, 55, 1610-1614.	0.9	35
64	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1034-1041.	0.5	33
65	Upregulation of the <i>N</i> -Formyl Peptide Receptors in Scleroderma Fibroblasts Fosters the Switch to Myofibroblasts. <i>Journal of Immunology</i> , 2015, 194, 5161-5173.	0.4	33
66	Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2020, 47, 881-887.	1.0	32
67	Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis. <i>PLoS ONE</i> , 2017, 12, e0183102.	1.1	32
68	Anti-hnRNP and other autoantibodies in systemic sclerosis with joint involvement. <i>Rheumatology</i> , 2009, 48, 920-925.	0.9	31
69	RANK-RANKL-OPG in Hemophilic Arthropathy: From Clinical and Imaging Diagnosis to Histopathology. <i>Journal of Rheumatology</i> , 2012, 39, 1678-1686.	1.0	31
70	High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2013, 15, R69.	1.6	31
71	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.5	31
72	Exercise Doppler Echocardiography Identifies Preclinic Asymptomatic Pulmonary Hypertension in Systemic Sclerosis. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 291-304.	1.8	30

#	ARTICLE	IF	CITATIONS
73	EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1178-1182.	0.5	30
74	Early Detection of Cardiac Involvement in Systemic Sclerosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 927-928.	2.3	30
75	Lack of activation of renal functional reserve predicts the risk of significant renal involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1963-1967.	0.5	29
76	Neuropeptides activate TRPV1 in rheumatoid arthritis fibroblast-like synoviocytes and foster IL-6 and IL-8 production. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1107-1109.	0.5	29
77	AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: A case report. <i>Journal of Medical Virology</i> , 2021, 93, 5718-5720.	2.5	29
78	Reduced circulating levels of angiotensin-(1 7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1305-1310.	0.5	28
79	Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 170-174.	1.0	27
80	The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. <i>Clinical Rheumatology</i> , 2020, 39, 2043-2047.	1.0	27
81	One year in review 2016: spondyloarthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 3-17.	0.4	27
82	Progressive Loss of Lymphatic Vessels in Skin of Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 297-301.	1.0	26
83	Immunosuppression for interstitial lung disease in systemic sclerosis. <i>European Respiratory Review</i> , 2013, 22, 236-243.	3.0	26
84	Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 221.	1.6	26
85	Proangiogenic effects of soluble Klotho on systemic sclerosis dermal microvascular endothelial cells. <i>Arthritis Research and Therapy</i> , 2017, 19, 27.	1.6	26
86	Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 1190-1197.	1.0	25
87	Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1665-1674.	0.5	25
88	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology</i> , The, 2021, 3, e166-e168.	2.2	25
89	One year in review 2021: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 3-12.	0.4	25
90	Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide. <i>PLoS ONE</i> , 2015, 10, e0130166.	1.1	24

#	ARTICLE	IF	CITATIONS
91	The "myth" of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?. <i>Arthritis Research and Therapy</i> , 2017, 19, 162.	1.6	24
92	Ilprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , 2019, 19, 357-366.	1.9	23
93	The origin of the myofibroblast in fibroproliferative vasculopathy: Does the endothelial cell steer the pathophysiology of systemic sclerosis?. <i>Arthritis and Rheumatism</i> , 2011, 63, 2164-2167.	6.7	22
94	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	0.9	20
95	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 181-185.	0.4	20
96	Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?. <i>Rheumatology</i> , 2014, 53, 975-987.	0.9	19
97	Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. <i>Arthritis Research and Therapy</i> , 2013, 15, R165.	1.6	18
98	Early detection of myocardial and pulmonary oedema with MRI in an asymptomatic systemic sclerosis patient: successful recovery with pulse steroid. <i>Rheumatology</i> , 2013, 52, 1920-1921.	0.9	17
99	Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist. <i>Journal of Rheumatology</i> , 2016, 43, 592-598.	1.0	17
100	Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. <i>Joint Bone Spine</i> , 2017, 84, 747-748.	0.8	17
101	Angiostatic and Angiogenic Chemokines in Systemic Sclerosis: An Overview. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 1-10.	1.0	17
102	<sup>18</sup> F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 577-578.	0.5	17
103	One year in review 2019: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 3-14.	0.4	17
104	The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?. <i>Arthritis Research and Therapy</i> , 2016, 18, 36.	1.6	16
105	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 603-608.	1.0	16
106	Glycolysis-derived acidic microenvironment as a driver of endothelial dysfunction in systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 4508-4519.	0.9	16
107	Stiff skin syndrome: evidence for an inflammation-independent fibrosis?. <i>Rheumatology</i> , 2009, 48, 849-852.	0.9	15
108	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021, 60, 728-736.	0.9	15

#	ARTICLE	IF	CITATIONS
109	Hemorheologic profile in systemic sclerosis: Role of NOS3 $\delta^{786T>C}$ and $894G>T$ polymorphisms in modulating both the hemorheologic parameters and the susceptibility to the disease. <i>Arthritis and Rheumatism</i> , 2006, 54, 2263-2270.	6.7	14
110	Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. <i>Rheumatology</i> , 2012, 51, 1042-1048.	0.9	14
111	Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 474-478.	0.5	14
112	One year in review 2018: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 3-23.	0.4	14
113	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015, 102, 19-24.	1.1	13
114	The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: a comprehensive overview. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091845.	1.2	13
115	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.5	12
116	Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. <i>Clinical Rheumatology</i> , 2021, 40, 1903-1912.	1.0	12
117	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	1.0	12
118	Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: Increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. <i>Arthritis and Rheumatism</i> , 2008, 58, 1226-1236.	6.7	11
119	Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiological Implications. <i>Journal of Clinical Medicine</i> , 2019, 8, 1256.	1.0	11
120	Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. <i>Rheumatology</i> , 2022, 61, SI56-SI64.	0.9	11
121	One year in review 2017: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 3-20.	0.4	11
122	Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?. <i>Clinical Rheumatology</i> , 2015, 34, 795-798.	1.0	10
123	Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. <i>Rheumatology</i> , 2020, 59, 3645-3656.	0.9	10
124	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	1.0	9
125	Systemic sclerosis sera affect fibrillin-1 deposition by dermal blood microvascular endothelial cells: therapeutic implications of cyclophosphamide. <i>Arthritis Research and Therapy</i> , 2013, 15, R90.	1.6	9
126	Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6189.	1.8	9



#	ARTICLE	IF	CITATIONS
127	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 90.	1.2	9
128	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , 2021, 20, 102981.	2.5	9
129	The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life. <i>Clinical Rheumatology</i> , 2022, 41, 573-579.	1.0	9
130	Angiotensin-Converting Enzyme in Systemic Sclerosis: From Endothelial Injury to a Genetic Polymorphism. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 10-19.	1.8	8
131	Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 575-577.	0.5	8
132	Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 6-20.	1.0	8
133	Microparticles and Kawasaki disease: a marker of vascular damage?. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S121-5.	0.4	8
134	Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis. <i>Diagnostics</i> , 2022, 12, 1696.	1.3	8
135	Avascular bone necrosis: An underestimated complication of systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, e3-e5.	1.6	7
136	The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. <i>European Journal of Internal Medicine</i> , 2019, 70, 43-49.	1.0	7
137	The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 241-246.	1.0	7
138	Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S148-52.	0.4	7
139	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	0.9	7
140	Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study. <i>Rheumatology</i> , 2019, 59, 580-585.	0.9	6
141	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110336.	1.2	6
142	One year in review 2020: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 3-17.	0.4	6
143	Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 288-289.	3.2	5
144	Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1310.	1.0	5

#	ARTICLE	IF	CITATIONS
145	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab015.	0.3	5
146	Ultrasound evaluation of bowel vasculopathy in systemic sclerosis. <i>European Journal of Internal Medicine</i> , 2022, 100, 62-68.	1.0	5
147	Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 179-183.	0.4	5
148	Disease Activity Improvement in Rheumatoid Arthritis Treated with Tumor Necrosis Factor- $\alpha$ Inhibitors Correlates with Increased Soluble Fas Levels. <i>Journal of Rheumatology</i> , 2014, 41, 1961-1965.	1.0	4
149	Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis. <i>Medicine (United States)</i> , 2019, 98, e16086.	0.4	4
150	Very early diagnosis of systemic sclerosis. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 18-23.	0.3	3
151	Recent updates in experimental protocols for endothelial cells. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 257-265.	1.0	3
152	Definition, Nomenclature, and Diagnostic Criteria. , 2015, , 13-19.		3
153	Early diagnosis of systemic sclerosis, where do we stand today?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1-3.	1.3	3
154	The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 135-141.	0.4	3
155	Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?. <i>Frontiers in Immunology</i> , 2022, 13, 887279.	2.2	2
156	Sociodemographic factors in fibromyalgia: results from the Italian Fibromyalgia Registry. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	2
157	Patient subgroups and potential risk factors in systemic sclerosis: is there a possibility of an early diagnosis?. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 555-564.	0.3	1
158	O16â€fA study examining the reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: challenges and insights for future clinical trial design. <i>Rheumatology</i> , 2018, 57, .	0.9	1
159	OP0239â€…PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE. , 2019, , .		1
160	OP0065â€…THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVELOP DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY. , 2019, , .		1
161	One year in review 2021: systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 3-12.	0.4	1
162	Fibromyalgia severity according to age categories: results of a cross-sectional study from a large national database. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	1

#	ARTICLE	IF	CITATIONS
163	TOPOISOMERASE-I (SCL-70) AUTOANTIBODIES. , 2007, , 231-238.		0
164	Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis. Annals of Internal Medicine, 2011, 155, 65.	2.0	0
165	Treatment options in systemic sclerosis. Expert Opinion on Orphan Drugs, 2013, 1, 851-865.	0.5	0
166	A10.9â€¦Evidence for Progressive Reduction and Loss of Telocytes in the Dermal Cellular Network of Systemic Sclerosis. Annals of the Rheumatic Diseases, 2013, 72, A75.1-A75.	0.5	0
167	Lâ€™hydroxychloroquine et les atteintes articulaires dans la sclérodermie systémique: résultats préliminaires d’une étude prospective cas-tmoins EUSTAR. Revue Du Rhumatisme (Edition Française) 2018, 85, 411-412.		0
168	SAT0265â€¦DETERMINANTS OF RENAL RESISTIVE INDEX (RRI) AT RENAL ARTERY DOPPLER ULTRASOUND IN SYSTEMIC SCLEROSIS (SSC): MORE THAN GENERAL POPULATION FACTORS. , 2019, , .		0
169	FRI0325â€¦IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS â€“ A EUSTAR DATABASE ANALYSIS. , 2019, , .		0
170	AB0369â€¦SAFETY, EFFICACY AND RETENTION RATE OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (BDMARDS) IN ASSOCIATION WITH DENOSUMAB: COMPARISON OF COMBINATION AND MONO-THERAPY REGIMENS. , 2019, , .		0
171	AB0639â€¦PREDICTION OF MAJOR VASCULAR COMPLICATIONS IN SYSTEMIC SCLEROSIS (SSC). , 2019, , .		0
172	FRI0314â€¦SENSITIVITY TO CHANGE AND RESPONSIVENESS TO TREATMENT OF RENAL RESISTIVE INDEX (IRR) IN SYSTEMIC SCLEROSIS (SSC). , 2019, , .		0
173	SAT0254â€¦VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
174	SAT0253â€¦PROGNOSTIC VALUE OF CARDIAC MAGNETIC RESONANCE IN SYSTEMIC SCLEROSIS. , 2019, , .		0
175	SAT0266â€¦DIGITAL ULCER (DU) AND VENTRICULAR ARRHYTHMIAS PREDICT THE LATE GADOLINIUM ENHANCEMENT (LGE) IN CARDIAC MAGNETIC RESONANCE (CMR) IN SYSTEMIC SCLEROSIS (SSC): PROPOSAL OF CANDIDATE RED FLAGS FOR EARLY REFERRAL. , 2019, , .		0
176	AB1355-HPRâ€¦A SYSTEMATIC LITERATURE REVIEW (SLR) ON NURSING SENSITIVE OUTCOMES IN SYSTEMIC SCLEROSIS (SSC). , 2019, , .		0
177	The emerging challenge of pain in systemic sclerosis: Similarity to the pain experience reported by Sjögren’s syndrome patients. Rheumatology and Immunology Research, 2021, 2, 113-119.	0.2	0
178	OUP accepted manuscript. Rheumatology, 2021, , .	0.9	0
179	Ultrasound in the diagnosis of morphea profunda and its complications: incarcerated digital extensor tendons. Rheumatology, 2021, , .	0.9	0
180	A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and the nervous systems. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 133-140.	0.4	0